Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 79: 106051, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31863923

ABSTRACT

OBJECTIVE: Statins have immunomodulatory potential in autoimmune diseases but had not been studied as a disease-modifying agent in inflammatory myopathies. The objective of this study is to assess the effect of simvastatin in an experimental model of autoimmune myositis in mice on muscle strength and histopathology. METHODS: Four groups of mice (n = 5 per group) were selected for experimentally induced myositis. Mice were immunized with 1.5 mg myosin in complete Freund's adjuvant weekly for two times and injected with 500 ng pertussis toxin twice immediately after each immunization. From day 1 before immunization to 10 days after the last immunization, mice were treated with oral simvastatin (10 or 20 or 40 mg/kg) diluted in DMSO. The control group mice were injected with complete Freund's adjuvant weekly for two times and did not receive treatment. Non-immunized mice (n = 5 per group) were treated either with simvastatin (5 mg/kg or 20 mg/kg or 40 mg/kg of simvastatin diluted in DMSO) or with DMSO. RESULTS: Inflammation was observed in myositis groups with positive myositis-specific antibodies. Muscle strength dropped significantly after immunization. Immunized simvastatin 20 mg/kg treated group had significantly higher muscle strength versus non-treated myositis mice and versus other simvastatin doses. Besides, a trend toward higher serum Th17 percentage population was found in immunized non-treated mice, versus immunized simvastatin- treated mice, without significant difference. CONCLUSION: Simvastatin at 20 mg/kg decreases the severity of myositis in experimental autoimmune myositis and is a candidate of being a disease-modifying agent in inflammatory myopathies.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Inflammation/drug therapy , Nervous System Autoimmune Disease, Experimental/drug therapy , Simvastatin/therapeutic use , Th17 Cells/immunology , Animals , Autoantibodies/blood , Autoantigens/immunology , Female , Humans , Mice , Mice, Inbred BALB C , Muscle Strength/drug effects , Myosins/immunology
2.
Physiol Res ; 68(5): 793-805, 2019 10 25.
Article in English | MEDLINE | ID: mdl-31424249

ABSTRACT

Intradialytic hypotension is a major complication during hemodialysis session, associated with increased risk of cardiovascular events and mortality. Its pathophysiology is believed to be multifactorial and remains not well elucidated. The aim of this study is to put forward new mechanisms behind the development of intradialytic hypotension. The study included sixty-five subjects on chronic hemodialysis, divided into two groups: intradialytic hypotensive (n=12) and normotensive (n=53), according to the variation of systolic blood pressure between post-dialysis and pre-dialysis measurements. Renin and angiotensin converting enzyme I plasma concentrations increased in both groups but more likely in normotensive group. Aldosterone plasma concentration is increased in the normotensive group while it decreased in the intradialytic hypotension group. Plasma endothelin concentrations showed higher values in intradialytic hypotension group. Post-dialysis asymmetric dimethylarginine and angiotensin converting enzyme 2 plasma concentrations were significantly higher in intradialytic hypotension group as compared to normotensive one. Collectrin plasma concentrations were significantly lower in intradialytic hypotension group. Finally, post-dialysis vascular endothelial growth factor C plasma concentration significantly increased in intradialytic hypotension group. In conclusion, endothelial dysfunction characterized by a lower level of vasoactive molecule seems to play a critical role in intradialytic hypotension development.


Subject(s)
Blood Pressure , Endothelium, Vascular/physiopathology , Hypotension/etiology , Kidney Diseases/therapy , Renal Dialysis/adverse effects , Aged , Aged, 80 and over , Aldosterone/blood , Angiotensin-Converting Enzyme 2 , Arginine/analogs & derivatives , Arginine/blood , Biomarkers/blood , Endothelin-1/blood , Endothelium, Vascular/metabolism , Female , Humans , Hypotension/blood , Hypotension/physiopathology , Kidney Diseases/blood , Kidney Diseases/physiopathology , Male , Membrane Glycoproteins/blood , Middle Aged , Peptidyl-Dipeptidase A/blood , Renin/blood , Time Factors , Vascular Endothelial Growth Factor C/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...